Yearly Archives2015

ExeGi Pharma Partners with NIH-Funded AIDS Clinical Trials Group to Study Probiotic in People Living with HIV standard

Researchers will explore potential role of probiotics in immune activation GAITHERSBURG, Md., Aug. 18, 2015 /PRNewswire-USNewswire/ — ExeGi Pharma has announced participation in a clinical trial funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to study the probiotic Visbiome™ in people living with HIV. Conducted by the NIH-funded AIDS Clinical Trials Group (ACTG), the study will evaluate the safety, tolerability and effect of probiotics on the gut microbiome and immune activation markers in people living with HIV who are currently on suppressive antiretroviral therapy (ART). In early stages of HIV infection, both the immune function of the gastrointestinal tract and its microbiome are altered and fail to normalize, even when ...

Continue Reading

This is a unique website which will require a more modern browser to work!

Please upgrade today!